Comparative Assessment of the Structural Features of Originator Recombinant Human Follitropin Alfa Versus Recombinant Human Follitropin Alfa Biosimilar Preparations Approved in Non-European Regions
Authors:
- Lucio ManziLMLucio Manzi
- Nunzio SepeNSNunzio Sepe
- Walter MigliaccioWMWalter Migliaccio
- Ludovica LanzoniLLLudovica Lanzoni
- Luisa IozzinoLILuisa Iozzino
- Fabrizia D’angeloFDFabrizia D’angelo
- Lucia ColarussoLCLucia Colarusso
- Susana MontenegroSMSusana Montenegro
- Angelo PalmeseAPAngelo Palmese
- Thomas D’hoogheTDThomas D’hooghe
- Alfredo Ulloa-AguirreAUAlfredo Ulloa-Aguirre
- Yulia KolodaYKYulia Koloda
Open Access
- 17 June 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (12) , 6762
Abstract
Although the full primary structures of the alfa and beta subunits of reference r-hFSH-alfa and its biosimilars are identical, cell context-dependent differences in the expressing cell lines and manufacturing process can lead to variations in glycosylation profiles. In the present study, we compared the structural features of reference r-hFSH-alfa with those of five biosimilar preparations approved in different global regions outside Europe (Primapur®, Jin Sai Heng®, Follitrope®, Folisurge®, and Corneumon®) with respect to glycosylation, macro- and microheterogeneity, and other post-translational modifications and higher order structure. The mean proportion of N-glycosylation-site occupancy was highest in reference r-hFSH-alfa, decreasing sequentially in Primapur, Jin Sai Heng, Corneumon, Follisurge and Follitrope, respectively. The level of antennarity showed slightly higher complexity in Corneumon, Primapur and Follitrope versus reference r-hFSH-alfa, whereas Jin Sai Heng and Folisurge were aligned with reference r-hFSH-alfa across all N-glycosylation sites. Sialylation level was higher in Corneumon and Follitrope, but small differences were detected in other biosimilar preparations compared with reference r-hFSH-alfa. Jin Sai Heng showed higher levels of N-glyconeuramic acid than the other preparations. Minor differences in oxidation levels were seen among the different products. Therefore, in summary, we identified var ious differences in N-glycosylation occupancy, antennarity, sialylation and oxidation between reference r-hFSH-alfa and the biosimilar preparations analyzed.Keywords
Funding Information
- Merck (CrossRef Funder ID: 10.13039/100009945)
This publication has 46 references indexed in Scilit:
- Ovarian stimulation protocols based on follicle-stimulating hormone glycosylation pattern: impact on oocyte quality and clinical outcomeFertility and Sterility, 2010
- Cumulative Live-Birth Rates after In Vitro FertilizationNew England Journal of Medicine, 2009
- Post-translational modifications in the context of therapeutic proteinsNature Biotechnology, 2006
- Comparative assessment of the consistency and quality of a highly purified FSH extracted from human urine (urofollitropin) and a recombinant human FSH (follitropin α)Reproductive BioMedicine Online, 2006
- What is the most relevant standard of success in assisted reproduction?Human Reproduction, 2004
- FSH isoform composition of commercial gonadotrophin preparations: a neglected aspect?Reproductive BioMedicine Online, 2004
- Intact follicle culture: what it can tell us aabout the roles of FSH glycoforms during follicle developmentReproductive BioMedicine Online, 2002
- Is there any physiological role for gonadotrophin oligosaccharide heterogeneity in humans?Human Reproduction, 2001
- Initial and Cyclic Recruitment of Ovarian Follicles*Endocrine Reviews, 2000
- Dynamics of basal and gonadotropin-releasing hormone-releasable serum follicle-stimulating hormone charge isoform distribution throughout the human menstrual cycle.The Journal of Clinical Endocrinology & Metabolism, 1995